Abstract
In Alzheimer disease, CSF biomarkers and nuclear imaging are of particular interest. Many studies investigated only one technique, limiting comparison. Here, in 76 patients blinded 99mTc-SPECT was compared to CSF. Sensitivity of CSF was 92%; and 51% for SPECT. Specificity favored SPECT (90 vs. 80%). Both techniques showed no coherence (p = 0.17–0.47). Our results confirm that CSF biomarkers show higher sensitivity. SPECT has higher specificity and can also be used for other dementias without established CSF biomarkers.
This is a preview of subscription content, log in via an institution to check access.
References
Ashford JW, Shih WJ, Coupal J, Shetty R, Schneider A, Cool C, Aleem A, Kiefer VH, Mendiondo MS, Schmitt FA (2000) Single SPECT measures of cerebral cortical perfusion reflect time-index estimation of dementia severity in Alzheimer’s disease. J Nucl Med 41(1):57–64
Dougall NJ, Bruggink S, Ebmeier KP (2004) Systematic review of the diagnostic accuracy of 99 mTc-HMPAO-SPECT in dementia. Am J Geriatr Psychiatry 12(6):554–570
Fink GR (2008) Herausforderungen in der Diagnostik demenzieller Erkrankungen. Fortschr Neurol Psychiatr 76(8):445–446
Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L (2006) Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5(3):228–234
Jobst KA, Barnetson LP, Shepstone BJ (1998) Accurate prediction of histologically confirmed Alzheimer’s disease and the differential diagnosis of dementia: the use of nincds-adrda and DSM-III-R criteria, SPECT, X-ray CT, and apo e4 in medial temporal lobe dementias. Oxford project to investigate memory and aging. Int Psychogeriatr 10(3):271–302
Lewczuk P, Esselmann H, Bibl M, Beck G, Maler JM, Otto M, Kornhuber J, Wiltfang J (2004a) Tau protein phosphorylated at threonine 181 in csf as a neurochemical biomarker in Alzheimer’s disease: original data and review of the literature. J Mol Neurosci 23(1–2):115–122
Lewczuk P, Esselmann H, Otto M, Maler JM, Henkel AW, Henkel MK, Eikenberg O, Antz C, Krause WR, Reulbach U, Kornhuber J, Wiltfang J (2004b) Neurochemical diagnosis of Alzheimer’s dementia by csf abeta42, abeta42/abeta40 ratio and total tau. Neurobiol Aging 25(3):273–281
Lewczuk P, Kornhuber J, Vanderstichele H, Vanmechelen E, Esselmann H, Bibl M, Wolf S, Otto M, Reulbach U, Kolsch H, Jessen F, Schroder J, Schonknecht P, Hampel H, Peters O, Weimer E, Perneczky R, Jahn H, Luckhaus C, Lamla U, Supprian T, Maler JM, Wiltfang J (2008) Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study. Neurobiol Aging 29(6):812–818
Lewczuk P, Zimmermann R, Wiltfang J, Kornhuber J (2009) Neurochemical dementia diagnostics: a simple algorithm for interpretation of the CSF biomarkers. J Neural Transm 116(9):1163–1167
Lewczuk P, Kamrowski-Kruck H, Peters O, Heuser I, Jessen F, Popp J, Bürger K, Hampel H, Frölich L, Wolf S, Prinz B, Jahn H, Luckhaus C, Perneczky R, Hüll M, Schröder J, Kessler H, Pantel J, Gertz HJ, Klafki HW, Kölsch H, Reulbach U, Esselmann H, Maler JM, Bibl M, Kornhuber J, Wiltfang J (2010) Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer’s disease: a multicenter study. Mol Psychiatry 15(2):138–145
Lobotesis K, Fenwick JD, Phipps A, Ryman A, Swann A, Ballard C, McKeith IG, O’Brien JT (2001) Occipital hypoperfusion on spect in dementia with lewy bodies but not ad. Neurology 56(5):643–649
Merhof D, Markiewicz PJ, Platsch G, Declerck J, Weih M, Kornhuber J, Kuwert T, Matthews JC, Herholz K (2010) Optimized data preprocessing for multivariate analysis applied to (99m)tc-ecd spect data sets of Alzheimer’s patients and asymptomatic controls. J Cereb Blood Flow Metab (Epub ahead of print)
Okamura N, Arai H, Maruyama M, Higuchi M, Matsui T, Tanji H, Seki T, Hirai H, Chiba H, Itoh M, Sasaki H (2002) Combined analysis of CSF Tau levels and [(123)i]iodoamphetamine spect in mild cognitive impairment: implications for a novel predictor of Alzheimer’s disease. Am J Psychiatry 159(3):474–476
Rodda J, Okello A, Edison P, Dannhauser T, Brooks DJ, Walker Z (2010) (11)C-PIB PET in subjective cognitive impairment. Eur Psychiatry 25(2):123–125
Shih WJ, Ashford JW, Coupal JJ, Ryo YU, Stipp VV, Magoun SL, Gross K (1999) Consecutive brain SPECT surface three-dimensional displays show progression of cerebral cortical abnormalities in Alzheimer’s disease. Clin Nucl Med 24(10):773–777
Tsolaki M, Sakka V, Gerasimou G, Dimacopoulos N, Chatzizisi O, Fountoulakis KN, Kyriazis G, Papanastasiou J, Kazis A (2001) Correlation of rCBF (SPECT), CSF Tau, and cognitive function in patients with dementia of the Alzheimer’s type, other types of dementia, and control subjects. Am J Alzheimers Dis Other Demen 16(1):21–31
Wallesch CW (2007) Verbesserte Demenzdiagnostik - und wie weiter? Fortschr Neurol Psychiatr 75(12):691–693
Weih M, Sulimma A-K, Lehfeld H, Niklewski G, Sonnenberg M, Richter-Schmidinger T, Alexopoulos P, Grässel E, Kornhuber J (2009) Vergleich der Therapiekonstanz von zwei regional benachbarten Gedächtnissprechstunden mit unterschiedlicher Struktur. Fortschr Neurol Psychiatr 77(4):212–217
Zimmermann R, Beck G, Knispel S, Maler JM, Weih M, Wiltfang J, Kornhuber J, Lewczuk P (2010) Intrathecal IgG synthesis in patients with alterations in the neurochemical dementia diagnostics. J Alzheimers Dis 19(4):1199–1203
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schmidt, D., Zimmermann, R., Lewczuk, P. et al. Confirmation rate of blinded 99mTc-SPECT compared to neurochemical dementia biomarkers in CSF in patients with Alzheimer disease. J Neural Transm 117, 1111–1114 (2010). https://doi.org/10.1007/s00702-010-0459-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-010-0459-7